1. Ruggiero, S. L. Et al. American association of oral and maxillofacialsurgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral Maxillofac. Surg. 2014;72, 938-1956.
2. Saad F, Brown JE, Van Poznak C, et al: Incidence, risk factors, andoutcomes of osteonecrosis of the jaw: Integrated analysis from threeblinded active-controlled phase III trials in cancer patients with bonemetastases. Ann Oncol 2012:23;1341.
3. Hallmer F, Andersson G, Gotrick B, et al: Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol126:477, 2018
4. Schiodt M, Vadhan-Raj S, Chambers MS, Nicolatou-Galitis O, PolitisC, Coropciuc R, Fedele S, Jandial D, Zhang J, Ma H, Saunders DP. Amulticenter case registry study onmedication-related osteonecrosis ofthe jaw in patients with advanced cancer. Support Care Cancer. 2018Jun;26(6):1905-1915.
5. Barasch, A. Et al. Risk factors for osteonecrosis of the jaws: A case-control study from the CONDOR Dental PBRN. J. Dent. Res. 90, 439-444 (2011).
6. Kyrgidis, A. Et al. Bisphosphonate-related osteonecrosis of the jaws:A case-control study of risk factors in breast cancer patients. J. Clin.Oncol. 26, 4634-4638 (2008).
7. Vahtsevanos, K. Et al. Longitudinal cohort study of risk factors incancer patients of bisphosphonate-related osteonecrosis of the jaw. J.Clin. Oncol. 27, 5356-5362 (2009)
8. Aljohani S, Fliefel R, Ihbe J, et al: What is the effect of antiresorptivedrugs (ARDs) on the development of medicationrelated osteonecrosisof the jaw (MRONJ) in osteoporosis patients: A systematic review. JCraniomaxillofac Surg 45:1493, 2017
9. Alesia K, Khalil HS. Reasons for and patterns relating to the extractionof permanent teeth in a subset of the Saudi population. Clin CosmetInvestig Dent 2013;5:51-6.
10. Anyanechi C, Chukwuneke F. Surve33 of the reasons for dentalextraction in Eastern Nigeria. Ann Med Health Sci Res 2012;2 (2):129-33.
11. Jovino-Silveira RC, Caldas A de F, de Souza EHA, Gusmao ES. ~Primary Reason for tooth extraction in a Brazilian adult population.Oral Heal Prev Dent 2005;3(3):151-7.
12. Lee CY, Chang YY, Shieh TY, Chang CS. Reasons for permanent toothExtractions in Taiwan. Asia-Pacific J Public Heal 2015;27(2):NP2350-7.
13. Lesolang RR, Motloba DP, Lalloo R. Patterns and reasons for toothextraction at the Winterveldt Clinic: 1998-2002. SADJ 2009;64(5):214-8.
14. Richards W, Ameen J, Coll AM, Higgs G. Reasons for toothextraction in four general dental practices in South Wales. Br Dent J2005;198(5):275-8.
15. Taiwo OA, Alabi OA, Yusuf OM, Ololo O, Olawole WO, Adeyemo WI.Reasons and pattern of tooth extraction among patients presentingat a Nigerian semi-rural specialist Hospital. Nig Q J Hosp Med2012;22(3):200-4.
16. Taiwo AO, Ibikunle AA, Braimah RO, Sulaiman OA, Gbotolorun OM.Tooth Extraction: pattern and etiology from extreme NorthwesternNigeria. Eur J Dent 2017;11(3):335-9.
17. Rayman S, Almas K, Dincer E. Bisphosphonate-related jaw necrosis: ateam approach management and prevention. Int J Dent Hyg 2009;7:90-5.
18. American Association of Oral and Maxillofacial Surgeons positionpaper on bisphosphonate-related osteonecrosis of the jaws. J OralMaxillofac Surg 2007;65: 369-76
19. Marx RE, Stern DS. Biopsy principles and techniques. Oral andMaxillofacial Patology: A rationale for Diagnosis And Treatment.Chicago: Quintessence, 2002:36-38.
20. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) inducedavascular necrosis of the jaws: a growing epidemic. J Oral MaxillofacSurg. 2003 Sep;61(9):1115-7.
21. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE,Mehrotra B; American Association of Oral and Maxillofacial Surgeons.American Association of Oral and Maxillofacial Surgeons positionpaper on bisphosphonate-related osteonecrosis of the jaws-2009 update.J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12.
22. Delmas PD, Meunier PJ: The Management of paget’s disease of bone. NEngl J Med 336:558, 1997
23. Terpos E, Raje N, Croucher P, et al: Denosumab compared withzoledronic acid on PFS in multiple myeloma: exploratory results of aninternational phase 3 study. Blood Adv 5:725, 2021
24. Fizazi K, Carducci M, Smith M, et al: Denosumab versus zoledronicacid for treatment of bone metastases in men with castration-resistantprostate cancer: A randomized, doubleblind study. Lancet 377:813, 2011
25. Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared withzoledronic acid for the treatment of bone metastases in patients withadvanced breast cancer: A randomized, doubleblind study. J Clin Oncol28:5132, 2010
26. Saag KG, Petersen J, Brandi ML, et al: Romosozumab or alendronate forfracture prevention in women with osteoporosis. N Engl J Med 377:1417,2017
27. Migliorati CA. Oral Complications in Cancer Patients-Medication-Related Osteonecrosis of the Jaw (MRONJ). Front Oral Health. 2022Apr 26;3:866871.
28. Glowacki J. Bisphosphosnates and bone. Ortho J at Harvard Med School2005;7:64.
29. Katz, H., Endodontic implications of bisphosphonate-associatedosteonecrosis of the jaws: a report of three cases. J Endod, 2005. 31(11):p. 831-4.p
30. Lam, D.K., et al., A review of bisphosphonate-associated osteonecrosisof the jaws and its management. J Can Dent Assoc, 2007. 73(5): p. 417-22
31. Russell, R.G., et al., Mechanisms of action of bisphosphonates:similarities and differences and their potential influence on clinicalefficacy. Osteoporos Int, 2008. 19(6): p. 733-59.
32. Goldvaser H, Amir E. Role of Bisphosphonates in Breast CancerTherapy. Curr Treat Options Oncol. 2019 Mar 14;20(4):26.
33. Bacci C, Cerrato A, Dotto V, Zambello R, Barilà G, Liço A, SemenzatoG, Stellini E, Zanette G. The Importance of Alliance betweenHematologists and Dentists: A Retrospective Study on the Developmentof Bisphosphonates Osteonecrosis of the Jaws (Bronj) in MultipleMyeloma Patients. Dent J (Basel). 2021 Jan 20;9(2):11.
34. Saad F, Sternberg CN, Mulders PFA, Niepel D, Tombal BF. The roleof bisphosphonates or denosumab in light of the availability of newtherapies for prostate cancer. Cancer Treat Rev. 2018 Jul;68:25-37.
35. Delmas PD: The use of bisphosphonates in the treatment ofOsteoporosis. Curr Opin Rheumatol 17:462, 2005
36. Delmas PD, Meunier PJ: The Management of Paget’s disease of bone. NEngl J Med 336:558, 1997
37. Letocha AD, Cintas HL, Troendle JF, et al: Controlled trial ofpamidronate in children with types III and IV Osteogenesis imperfectaconfirms vertebral gains but not short-term functional improvement. JBone Miner Res 20:977, 2005
38. Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, BohlkeK, Ruggiero SL, et al. Medication-Related Osteonecrosis of theJaw:MASCC/ISOO/ASCO Clinical Practice Guideline. Clin Oncol.(2019) 37:2270-90.
39. Holtmann, H.; Lommen, J.; Kübler, N.R.; Sproll, C.; Rana, M.;Karschuck, P.; Depprich, R. Pathogenesis of medication-relatedosteonecrosis of the jaw: A comparative study of in vivo and in vitrotrials. J. Int. Med. Res. 2018, 46, 4277-4296
40. Kuehn S, Scariot R, Elsalanty M. Medication-Related Osteonecrosis:Why the Jawbone? Dent J (Basel). 2023 Apr 23;11(5):109.
41. Sobczak-Jaskow H, Kochanska B, Drogoszewska B. A Study of OralHealth Parameters and the Properties and Composition of Salivain Oncological Patients with and without Medication-RelatedOsteonecrosis of the Jaw Who Take Bisphosphonates. Medicina(Kaunas). 2023 Jun 2;59(6):1073.
42. Otto, S.; Aljohani, S.; Fliefel, R.; Ecke, S.; Ristow, O.; Burian, E.;Troeltzsch, M.; Pautke, C.; Ehrenfeld, M. Infection as an ImportantFactor in Medication-Related Osteonecrosis of the Jaw (MRONJ).Medicina 2021, 57, 463.
43. Soutome, S.; Otsuru, M.; Hayashida, S.; Murata, M.; Yanamoto, S.;Sawada, S.; Kojima, Y.; Funahara, M.; Iwai, H.; Umeda, M.; et al.Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci. Rep. 2021, 11,17226.
44. Kang, S.H.; Park, S.J.; Kim, M.K. The effect of bisphosphonatediscontinuation on the incidence of postoperative medication-relatedosteonecrosis of the jaw after tooth extraction. J. Korean Assoc. OralMaxillofac. Surg. 2020, 46, 78-83.
45. Ruggiero, S.L.; Dodson, T.B.; Aghaloo, T.; Carlson, E.R.; Ward,B.B.; Kademani, D. American Association of Oral and MaxillofacialSurgeons’ Position Paper on Medication-Related Osteonecrosis of theJaws-2022 Update. J. Oral Maxillofac. Surg. 2022, 80, 920-943.
46. de Molon RS, Hsu C, Bezouglaia O, Dry SM, Pirih FQ, Soundia A,Cunha FQ, Cirelli JA, Aghaloo TL, Tetradis S. Rheumatoid ArthritisExacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. ARandomized, Prospective, Controlled Animal Study. J Bone Miner Res.2016 Aug;31(8):1596-607.
47. D’Agostino S, Valentini G, Dolci M, Ferrara E. Potential Relationshipbetween Poor Oral Hygiene and MRONJ: An ObservationalRetrospective Study. Int J Environ Res Public Health. 2023 Apr5;20(7):5402.
48. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, KademaniD. American Association of Oral and Maxillofacial Surgeons’ PositionPaper on Medication-Related Osteonecrosis of the Jaws-2022 Update. JOral Maxillofac Surg. 2022 May;80(5):920-943.
49. Khominsky A, Lim M. “Spontaneous” medication-related osteonecrosisof the jaw; two case reports and a systematic review. Aust Dent J. 2018Dec;63(4):441-454.
50. Vandone AM, Donadio M, Mozzati M, et al: Impact of dental care inthe prevention of bisphosphonate-associated osteonecrosis of the jaw: Asingle-center clinical experience. Ann Oncol 23:193, 2012
51. Otto, S. Et al. Tooth extraction in patients receiving oral or intravenousbisphosphonate administration: A Trigger for BRONJ development?. J.Craniomaxillofac. Surg. 43, 847-854 (2015)
52. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-inducedexposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors,recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005Nov;63(11):1567-75.
53. Jardim Caldas R, Spíndola Antunes H, de Oliveira Rodini Pegoraro C,Ribeiro Guedes F, da Silva Santos PS. Oral health condition in cancerpatients under bisphosphonate therapy. Support Care Cancer. 2021Dec;29(12):7687-7694.
54. Petersen P E, Bourgeois D, Ogawa H, Estupinan-Day S, Ndiaye C.The global burden of oral diseases and risks to oral health. Bull WorldHealth Organ 2005; 83:661-669.
55. Marcenes W, Kassebaum N J, Bernabe E et al. Global burden of oralconditions in 1990-2010: a systematic analysis. J Dent Res 2013; 92: 592-597.
56. Kassebaum N J, Bernabe E, Dahiya M, Bhandari B, Murray C J,Marcenes W. Global burden of untreated caries: A systematic reviewand metaregression. J Dent Res 2015; 94: 650-658.
57. Kos M. Association of dental and periodontal status withbisphosphonate-related osteonecrosis of the jaws. A retrospective casecontrolled study. Arch Med Sci. 2014 Feb 24;10(1):117-23.
58. Sobczak-Jaskow H, Kochanska B, Drogoszewska B. A Study of OralHealth Parameters and the Properties and Composition of Salivain Oncological Patients with and without Medication-RelatedOsteonecrosis of the Jaw Who Take Bisphosphonates. Medicina(Kaunas). 2023 Jun 2;59(6):1073.
59. Stockmann P, Ebker T, Bergauer J, Wehrhan F. Saliva diagnostics inpatients suffering from bisphosphonate-associated osteonecrosis of thejaw: Results of an observational study. J Craniomaxillofac Surg. 2020Feb;48(2):176-180.
60. Zirk M, Wenzel C, Buller J, Zöller JE, Zinser M, Peters F. Microbialdiversity in infections of patients with medication-related osteonecrosisof the jaw. Clin Oral Investig. 2019 May;23(5):2143-2151.
61. Bowler PG, Duerden BI, Armstrong DG Wound microbiology andassociated approaches to wound management. Clin Microbiol Rev 2001,14(2):244-269.